Although a main mechanism of resistance to RAF or MEK inhibitors is reactivation of ERK signaling [18,19,20], resistance mechanisms to combined RAF and MEK inhibition increasingly include the activation of alternative pathways that can drive cancer cell proliferation and survival [21,22]. This evidence concerns the gene MAP2K7 and cancer.